Biopharmaceutical Fermentation Systems

Biopharmaceutical Fermentation Systems

Global Biopharmaceutical Fermentation Systems Market to Reach $17.3 Billion by 2030
The global market for Biopharmaceutical Fermentation Systems estimated at US$12.7 Billion in the year 2023, is expected to reach US$17.3 Billion by 2030, growing at a CAGR of 4.5% over the period 2023-2030. Upstream Products, one of the segments analyzed in the report, is expected to record 3.7% CAGR and reach US$5.9 Billion by the end of the analysis period. Growth in the Downstream Products segment is estimated at 4.9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $3.8 Billion, While China is Forecast to Grow at 4.3% CAGR
The Biopharmaceutical Fermentation Systems market in the U.S. is estimated at US$3.8 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.1 Billion by the year 2030 trailing a CAGR of 4.3% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.6% and 3.6% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

What to Expect from the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 41 Featured) -
  • Becton, Dickinson and Company
  • Eppendorf AG
  • F. Hoffmann-La Roche AG
  • GE Healthcare
  • Lonza Group AG
  • Merck KgaA
  • Nova Biomedical Corporation
  • Sartorius Stedim Biotech SA
  • Thermo Fisher Scientific, Inc.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Biopharmaceutical Fermentation Systems - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
Global Economic Update
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Biopharmaceutical Fermentation Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Biopharmaceutical Fermentation Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Upstream Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Upstream Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Upstream Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Downstream Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Downstream Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Downstream Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Recombinant Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for Recombinant Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for Recombinant Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 14: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 15: World 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 17: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 18: World 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 19: World Recent Past, Current & Future Analysis for Probiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 20: World Historic Review for Probiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 21: World 16-Year Perspective for Probiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 22: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 23: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 24: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 25: World Recent Past, Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 26: World Historic Review for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 27: World 16-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 28: World Recent Past, Current & Future Analysis for Contract Manufacturing Organizations (CMOs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 29: World Historic Review for Contract Manufacturing Organizations (CMOs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 30: World 16-Year Perspective for Contract Manufacturing Organizations (CMOs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 31: World Recent Past, Current & Future Analysis for Contract Research Organizations (CROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 32: World Historic Review for Contract Research Organizations (CROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 33: World 16-Year Perspective for Contract Research Organizations (CROs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 34: World Recent Past, Current & Future Analysis for Academic and Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 35: World Historic Review for Academic and Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 36: World 16-Year Perspective for Academic and Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 37: World Recent Past, Current & Future Analysis for Food Industry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 38: World Historic Review for Food Industry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 39: World 16-Year Perspective for Food Industry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 40: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 41: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 42: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 43: World Biopharmaceutical Fermentation Systems Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Biopharmaceutical Fermentation Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 44: USA Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Product - Upstream Products and Downstream Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: USA Historic Review for Biopharmaceutical Fermentation Systems by Product - Upstream Products and Downstream Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: USA 16-Year Perspective for Biopharmaceutical Fermentation Systems by Product - Percentage Breakdown of Value Sales for Upstream Products and Downstream Products for the Years 2014, 2024 & 2030
TABLE 47: USA Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Application - Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: USA Historic Review for Biopharmaceutical Fermentation Systems by Application - Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: USA 16-Year Perspective for Biopharmaceutical Fermentation Systems by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications for the Years 2014, 2024 & 2030
TABLE 50: USA Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by End-Use - Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: USA Historic Review for Biopharmaceutical Fermentation Systems by End-Use - Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: USA 16-Year Perspective for Biopharmaceutical Fermentation Systems by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses for the Years 2014, 2024 & 2030
CANADA
TABLE 53: Canada Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Product - Upstream Products and Downstream Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: Canada Historic Review for Biopharmaceutical Fermentation Systems by Product - Upstream Products and Downstream Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Canada 16-Year Perspective for Biopharmaceutical Fermentation Systems by Product - Percentage Breakdown of Value Sales for Upstream Products and Downstream Products for the Years 2014, 2024 & 2030
TABLE 56: Canada Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Application - Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Canada Historic Review for Biopharmaceutical Fermentation Systems by Application - Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Canada 16-Year Perspective for Biopharmaceutical Fermentation Systems by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications for the Years 2014, 2024 & 2030
TABLE 59: Canada Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by End-Use - Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Canada Historic Review for Biopharmaceutical Fermentation Systems by End-Use - Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Canada 16-Year Perspective for Biopharmaceutical Fermentation Systems by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses for the Years 2014, 2024 & 2030
JAPAN
Biopharmaceutical Fermentation Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 62: Japan Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Product - Upstream Products and Downstream Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: Japan Historic Review for Biopharmaceutical Fermentation Systems by Product - Upstream Products and Downstream Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: Japan 16-Year Perspective for Biopharmaceutical Fermentation Systems by Product - Percentage Breakdown of Value Sales for Upstream Products and Downstream Products for the Years 2014, 2024 & 2030
TABLE 65: Japan Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Application - Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: Japan Historic Review for Biopharmaceutical Fermentation Systems by Application - Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: Japan 16-Year Perspective for Biopharmaceutical Fermentation Systems by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications for the Years 2014, 2024 & 2030
TABLE 68: Japan Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by End-Use - Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Japan Historic Review for Biopharmaceutical Fermentation Systems by End-Use - Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Japan 16-Year Perspective for Biopharmaceutical Fermentation Systems by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses for the Years 2014, 2024 & 2030
CHINA
Biopharmaceutical Fermentation Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 71: China Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Product - Upstream Products and Downstream Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: China Historic Review for Biopharmaceutical Fermentation Systems by Product - Upstream Products and Downstream Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: China 16-Year Perspective for Biopharmaceutical Fermentation Systems by Product - Percentage Breakdown of Value Sales for Upstream Products and Downstream Products for the Years 2014, 2024 & 2030
TABLE 74: China Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Application - Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: China Historic Review for Biopharmaceutical Fermentation Systems by Application - Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: China 16-Year Perspective for Biopharmaceutical Fermentation Systems by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications for the Years 2014, 2024 & 2030
TABLE 77: China Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by End-Use - Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: China Historic Review for Biopharmaceutical Fermentation Systems by End-Use - Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: China 16-Year Perspective for Biopharmaceutical Fermentation Systems by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses for the Years 2014, 2024 & 2030
EUROPE
Biopharmaceutical Fermentation Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 80: Europe Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 81: Europe Historic Review for Biopharmaceutical Fermentation Systems by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Europe 16-Year Perspective for Biopharmaceutical Fermentation Systems by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 83: Europe Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Product - Upstream Products and Downstream Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Europe Historic Review for Biopharmaceutical Fermentation Systems by Product - Upstream Products and Downstream Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Europe 16-Year Perspective for Biopharmaceutical Fermentation Systems by Product - Percentage Breakdown of Value Sales for Upstream Products and Downstream Products for the Years 2014, 2024 & 2030
TABLE 86: Europe Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Application - Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Europe Historic Review for Biopharmaceutical Fermentation Systems by Application - Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Europe 16-Year Perspective for Biopharmaceutical Fermentation Systems by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications for the Years 2014, 2024 & 2030
TABLE 89: Europe Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by End-Use - Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Europe Historic Review for Biopharmaceutical Fermentation Systems by End-Use - Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Europe 16-Year Perspective for Biopharmaceutical Fermentation Systems by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses for the Years 2014, 2024 & 2030
FRANCE
Biopharmaceutical Fermentation Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 92: France Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Product - Upstream Products and Downstream Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: France Historic Review for Biopharmaceutical Fermentation Systems by Product - Upstream Products and Downstream Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: France 16-Year Perspective for Biopharmaceutical Fermentation Systems by Product - Percentage Breakdown of Value Sales for Upstream Products and Downstream Products for the Years 2014, 2024 & 2030
TABLE 95: France Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Application - Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: France Historic Review for Biopharmaceutical Fermentation Systems by Application - Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: France 16-Year Perspective for Biopharmaceutical Fermentation Systems by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications for the Years 2014, 2024 & 2030
TABLE 98: France Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by End-Use - Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: France Historic Review for Biopharmaceutical Fermentation Systems by End-Use - Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: France 16-Year Perspective for Biopharmaceutical Fermentation Systems by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses for the Years 2014, 2024 & 2030
GERMANY
Biopharmaceutical Fermentation Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 101: Germany Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Product - Upstream Products and Downstream Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Germany Historic Review for Biopharmaceutical Fermentation Systems by Product - Upstream Products and Downstream Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Germany 16-Year Perspective for Biopharmaceutical Fermentation Systems by Product - Percentage Breakdown of Value Sales for Upstream Products and Downstream Products for the Years 2014, 2024 & 2030
TABLE 104: Germany Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Application - Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Germany Historic Review for Biopharmaceutical Fermentation Systems by Application - Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Germany 16-Year Perspective for Biopharmaceutical Fermentation Systems by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications for the Years 2014, 2024 & 2030
TABLE 107: Germany Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by End-Use - Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Germany Historic Review for Biopharmaceutical Fermentation Systems by End-Use - Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Germany 16-Year Perspective for Biopharmaceutical Fermentation Systems by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses for the Years 2014, 2024 & 2030
ITALY
TABLE 110: Italy Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Product - Upstream Products and Downstream Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Italy Historic Review for Biopharmaceutical Fermentation Systems by Product - Upstream Products and Downstream Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Italy 16-Year Perspective for Biopharmaceutical Fermentation Systems by Product - Percentage Breakdown of Value Sales for Upstream Products and Downstream Products for the Years 2014, 2024 & 2030
TABLE 113: Italy Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Application - Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Italy Historic Review for Biopharmaceutical Fermentation Systems by Application - Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Italy 16-Year Perspective for Biopharmaceutical Fermentation Systems by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications for the Years 2014, 2024 & 2030
TABLE 116: Italy Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by End-Use - Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: Italy Historic Review for Biopharmaceutical Fermentation Systems by End-Use - Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: Italy 16-Year Perspective for Biopharmaceutical Fermentation Systems by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses for the Years 2014, 2024 & 2030
UNITED KINGDOM
Biopharmaceutical Fermentation Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 119: UK Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Product - Upstream Products and Downstream Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: UK Historic Review for Biopharmaceutical Fermentation Systems by Product - Upstream Products and Downstream Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: UK 16-Year Perspective for Biopharmaceutical Fermentation Systems by Product - Percentage Breakdown of Value Sales for Upstream Products and Downstream Products for the Years 2014, 2024 & 2030
TABLE 122: UK Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Application - Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: UK Historic Review for Biopharmaceutical Fermentation Systems by Application - Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: UK 16-Year Perspective for Biopharmaceutical Fermentation Systems by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications for the Years 2014, 2024 & 2030
TABLE 125: UK Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by End-Use - Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: UK Historic Review for Biopharmaceutical Fermentation Systems by End-Use - Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: UK 16-Year Perspective for Biopharmaceutical Fermentation Systems by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Product - Upstream Products and Downstream Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: Rest of Europe Historic Review for Biopharmaceutical Fermentation Systems by Product - Upstream Products and Downstream Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: Rest of Europe 16-Year Perspective for Biopharmaceutical Fermentation Systems by Product - Percentage Breakdown of Value Sales for Upstream Products and Downstream Products for the Years 2014, 2024 & 2030
TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Application - Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: Rest of Europe Historic Review for Biopharmaceutical Fermentation Systems by Application - Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: Rest of Europe 16-Year Perspective for Biopharmaceutical Fermentation Systems by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications for the Years 2014, 2024 & 2030
TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by End-Use - Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 135: Rest of Europe Historic Review for Biopharmaceutical Fermentation Systems by End-Use - Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: Rest of Europe 16-Year Perspective for Biopharmaceutical Fermentation Systems by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Biopharmaceutical Fermentation Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Product - Upstream Products and Downstream Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 138: Asia-Pacific Historic Review for Biopharmaceutical Fermentation Systems by Product - Upstream Products and Downstream Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: Asia-Pacific 16-Year Perspective for Biopharmaceutical Fermentation Systems by Product - Percentage Breakdown of Value Sales for Upstream Products and Downstream Products for the Years 2014, 2024 & 2030
TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Application - Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 141: Asia-Pacific Historic Review for Biopharmaceutical Fermentation Systems by Application - Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: Asia-Pacific 16-Year Perspective for Biopharmaceutical Fermentation Systems by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications for the Years 2014, 2024 & 2030
TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by End-Use - Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Asia-Pacific Historic Review for Biopharmaceutical Fermentation Systems by End-Use - Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Asia-Pacific 16-Year Perspective for Biopharmaceutical Fermentation Systems by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses for the Years 2014, 2024 & 2030
REST OF WORLD
TABLE 146: Rest of World Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Product - Upstream Products and Downstream Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Rest of World Historic Review for Biopharmaceutical Fermentation Systems by Product - Upstream Products and Downstream Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Rest of World 16-Year Perspective for Biopharmaceutical Fermentation Systems by Product - Percentage Breakdown of Value Sales for Upstream Products and Downstream Products for the Years 2014, 2024 & 2030
TABLE 149: Rest of World Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by Application - Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Rest of World Historic Review for Biopharmaceutical Fermentation Systems by Application - Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Rest of World 16-Year Perspective for Biopharmaceutical Fermentation Systems by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Probiotics and Other Applications for the Years 2014, 2024 & 2030
TABLE 152: Rest of World Recent Past, Current & Future Analysis for Biopharmaceutical Fermentation Systems by End-Use - Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: Rest of World Historic Review for Biopharmaceutical Fermentation Systems by End-Use - Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: Rest of World 16-Year Perspective for Biopharmaceutical Fermentation Systems by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic and Research Institutes, Food Industry and Other End-Uses for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings